| Next generation sequencing in cancer research and clinical application D Shyr, Q Liu Biological procedures online 15, 1-11, 2013 | 169 | 2013 |
| Identity-by-descent detection across 487,409 British samples reveals fine scale population structure and ultra-rare variant associations J Nait Saada, G Kalantzis, D Shyr, F Cooper, M Robinson, A Gusev, ... Nature communications 11 (1), 6130, 2020 | 77 | 2020 |
| Unraveling attributes of COVID-19 vaccine hesitancy and uptake in the US: A large nationwide study SD McCabe, EA Hammershaimb, D Cheng, A Shi, D Shyr, S Shen, ... MedRxiv, 2021.04. 05.21254918, 2021 | 35 | 2021 |
| Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma … K Campbell, D Shyr, R Bagatell, M Fischer, A Nakagawara, AC Nieto, ... Pediatric blood & cancer 66 (8), e27819, 2019 | 26 | 2019 |
| Feasibility of systematic poverty screening in a pediatric oncology referral center DJ Zheng, D Shyr, C Ma, AC Muriel, J Wolfe, K Bona Pediatric blood & cancer 65 (12), e27380, 2018 | 21 | 2018 |
| What constitutes a valid surrogate end point in cancer clinical trials? Y Shyr, D Shyr JAMA oncology 6 (9), 1334-1335, 2020 | 8 | 2020 |
| Unraveling attributes of COVID-19 vaccine acceptance and uptake in the US: a large nationwide study SD McCabe, EA Hammershaimb, D Cheng, A Shi, D Shyr, S Shen, ... Scientific Reports 13 (1), 8360, 2023 | 6 | 2023 |
| Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma K Fanucci, MJ Pilat, D Shyr, Y Shyr, S Boerner, J Li, D Durecki, J Drappatz, ... Cancer Research Communications 3 (2), 192-201, 2023 | 4 | 2023 |
| Sample size calculation of RNA-sequencing experiment: a simulation-based approach of TCGA data D Shyr, CI Li J Biomet Biostat 5 (198), 2, 2014 | 3 | 2014 |
| Evaluating Neighborhood-Level Differences in Hair Product Safety by Environmental Working Group Ratings among Retailers in Boston, Massachusetts M Chan, S Parikh, D Shyr, B Shamasunder, G Adamkiewicz, ... Environmental Health Perspectives 131 (9), 097002, 2023 | 2 | 2023 |
| Abstract CT145: Olaparib+/-atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter … KA Fanucci, MJ Pilat, D Shyr, Y Shyr, SA Boerner, D Durecki, A Noonan, ... Cancer Research 83 (8_Supplement), CT145-CT145, 2023 | 2 | 2023 |
| The design and analysis of non-randomized studies: a case study of off-label use of hydroxychloroquine in the COVID-19 pandemic D Shyr, Y Shyr Expert Opinion on Investigational Drugs 30 (2), 111-117, 2021 | 2 | 2021 |
| EPID-01. comparative survival analysis of pediatric central nervous system tumors between Boston and Egypt E Auwarter, D Shyr, C Ma, AA Aziz, I Maher, A El Haddad, A Ibrahim, ... Neuro-Oncology 20 (Suppl 2), i80, 2018 | 2 | 2018 |
| Sample Size Calculation for Differential Expression Analysis of RNA-Seq Data SP Hoskins, D Shyr, Y Shyr Frontiers of Biostatistical Methods and Applications in Clinical Oncology …, 2017 | 1 | 2017 |
| Decoding biological age from face photographs using deep learning O Zalay, D Bontempi, DS Bitterman, N Birkbak, D Shyr, F Haugg, JM Qian, ... medRxiv, 2023 | | 2023 |
| Statistical and Machine Learning Methods for Assessing Hardy-Weinberg Equilibrium in Large-Scale Multi-Ethnic Whole Genome Sequencing Studies D Shyr Harvard University, 2023 | | 2023 |
| Comparison of toxicity following single versus tandem autologous transplant regimens for pediatric medulloblastoma AS Plant‐Fox, C Ma, H Al‐Sayegh, D Shyr, MA Lee, LE Lehmann, SN Chi Pediatric Transplantation 26 (4), e14229, 2022 | | 2022 |
| Unraveling Attributes of COVID-19 Vaccine Hesitancy in the US: A Large Nationwide Study (preprint) S McCabe, E Hammershaimb, D Cheng, A Shi, D Shyr, S Shen, L Cole, ... | | 2021 |
| MBCL-10. TREATMENT OUTCOMES AND COMPLICATION RATES OF SINGLE VERSUS TANDEM AUTOLOGOUS TRANSPLANT FOR REGIMENS FOR MEDULLOBLASTOMA AS Plant, C Ma, D Shyr, MA Lee, SN Chi Neuro-Oncology 20 (Suppl 2), i119, 2018 | | 2018 |
